Literature DB >> 33753366

Caring for people who inject drugs when they are admitted to hospital.

Thomas D Brothers1, John Fraser2, Duncan Webster2.   

Abstract

Entities:  

Year:  2021        PMID: 33753366      PMCID: PMC8096383          DOI: 10.1503/cmaj.202124

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.

Injection drug use and associated hospital admissions are increasingly common in Canada

The number of people who inject drugs in Canada increased from 130 000 in 2011 to 171 900 in 2016.1 Reported hospital admissions for patients with injection-associated infective endocarditis in Ontario increased 5-fold from 34 in 1997 to 176 in 2014.2

People who inject drugs may not be comfortable disclosing substance use

Clinicians should use a nonjudgmental approach to ask their patients about type, quantity and frequency of substance use. Illicit substance use is stigmatized and criminalized, which affects hospital care.3,4 People who inject drugs ask for care that prioritizes trust and relationships, recognizes power imbalances and gives patients space.3

Starting treatment for substance use disorders in hospital improves outcomes

A randomized controlled trial5 and several cohort studies4,6 found inhospital initiation of opioid agonist treatment (e.g., buprenorphine or methadone) for opioid use disorder was associated with increased engagement with treatment and decreased readmissions or death, compared with outpatient referrals. All physicians can prescribe buprenorphine or methadone in hospital, although some provincial medical regulators require certification to initiate opioid agonist treatment. Addiction medicine consultation services can assist with complex diagnosis and management issues, including stimulant and polysubstance use disorders.4

Effectively treating opioid withdrawal reduces premature patient-initiated discharges against medical advice

People who inject drugs describe leaving hospital prematurely because of undertreated withdrawal and pain.3 Most people who inject drugs use opioids,1 and opioid medications are far more effective than nonopioids (e.g., clonidine) at relieving opioid withdrawal symptoms and facilitating hospital care.3,4 If patients decline opioid agonist treatment, physicians should consider frequent dosing of short-acting opioids (e.g., hydromorphone every 3 h), titrated to symptom relief.4 Treating withdrawal or pain with opioids does not “worsen” addiction. Shared decision-making is essential.4

Hospitals should offer harm reduction services

Hospitals need to change traditional abstinence-only policies.4 Harm reduction services, such as peer support, sterile injection equipment and disposal containers, take-home naloxone kits and supervised consumption facilities, should be offered by hospitals. When provided, these evidence-based services help reduce risks of infection and overdose among inpatients.4
  3 in total

1.  Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.

Authors:  Jane M Liebschutz; Denise Crooks; Debra Herman; Bradley Anderson; Judith Tsui; Lidia Z Meshesha; Shernaz Dossabhoy; Michael Stein
Journal:  JAMA Intern Med       Date:  2014-08       Impact factor: 21.873

2.  Addiction Medicine Consultations Reduce Readmission Rates for Patients With Serious Infections From Opioid Use Disorder.

Authors:  Laura R Marks; Satish Munigala; David K Warren; Stephen Y Liang; Evan S Schwarz; Michael J Durkin
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

3.  Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada.

Authors:  Brendan Jacka; Sarah Larney; Louisa Degenhardt; Naveed Janjua; Stine Høj; Mel Krajden; Jason Grebely; Julie Bruneau
Journal:  Am J Public Health       Date:  2019-11-14       Impact factor: 9.308

  3 in total
  7 in total

1.  Opioid agonist treatment and risk of death or rehospitalization following injection drug use-associated bacterial and fungal infections: A cohort study in New South Wales, Australia.

Authors:  Thomas D Brothers; Dan Lewer; Nicola Jones; Samantha Colledge-Frisby; Michael Farrell; Matthew Hickman; Duncan Webster; Andrew Hayward; Louisa Degenhardt
Journal:  PLoS Med       Date:  2022-07-19       Impact factor: 11.613

2.  Linking opioid use disorder treatment from hospital to community.

Authors:  Thomas D Brothers; Dan Lewer; Ashish P Thakrar
Journal:  Addiction       Date:  2021-03-18       Impact factor: 7.256

3.  Unequal access to opioid agonist treatment and sterile injecting equipment among hospitalized patients with injection drug use-associated infective endocarditis.

Authors:  Thomas D Brothers; Kimiko Mosseler; Susan Kirkland; Patti Melanson; Lisa Barrett; Duncan Webster
Journal:  PLoS One       Date:  2022-01-26       Impact factor: 3.240

4.  Fatal opioid overdoses during and shortly after hospital admissions in England: A case-crossover study.

Authors:  Dan Lewer; Brian Eastwood; Martin White; Thomas D Brothers; Martin McCusker; Caroline Copeland; Michael Farrell; Irene Petersen
Journal:  PLoS Med       Date:  2021-10-05       Impact factor: 11.069

5.  Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness.

Authors:  Thomas D Brothers; Malcolm Leaman; Matthew Bonn; Dan Lewer; Jacqueline Atkinson; John Fraser; Amy Gillis; Michael Gniewek; Leisha Hawker; Heather Hayman; Peter Jorna; David Martell; Tiffany O'Donnell; Helen Rivers-Bowerman; Leah Genge
Journal:  Drug Alcohol Depend       Date:  2022-04-07       Impact factor: 4.852

6.  Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder.

Authors:  Thomas D Brothers; John Fraser; Emily MacAdam; Brendan Morgan; Duncan Webster
Journal:  Drug Alcohol Rev       Date:  2021-08-04

7.  Social and structural determinants of injecting-related bacterial and fungal infections among people who inject drugs: protocol for a mixed studies systematic review.

Authors:  Thomas D Brothers; Dan Lewer; Matthew Bonn; Duncan Webster; Magdalena Harris
Journal:  BMJ Open       Date:  2021-08-09       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.